Philips introduces first at-home, 12-lead ECG integrated solution for decentralized clinical trials
Philips has launched the first full-service, at-home, 12-lead ECG solution tailored for decentralized clinical trials. This clinical-grade ECG aims to enhance patient recruitment, compliance, and retention by minimizing the necessity for site visits. With data readings comparable to traditional site-based ECGs, the innovative solution utilizes the PCA 500 ECG patch for secure, real-time data transmission. Philips’ advanced monitoring services have supported over 2,000 clinical trials globally. This new offering is already available in select markets across North America, Europe, and Asia.
- Introduction of the first at-home, 12-lead ECG solution for decentralized clinical trials.
- Enhances patient recruitment, compliance, and retention by reducing site visits.
- Utilizes PCA 500 ECG patch technology for high-quality data recording.
- Philips has supported over 2,000 clinical trials, enhancing credibility.
- None.
January 26, 2022
Philips expands remote cardiac monitoring portfolio with patch-based, clinical-grade ECG designed to improve patient recruitment, compliance and retention by reducing need for site visits during clinical trials
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the introduction of the industry’s first full-service, at-home, 12-lead electrocardiogram (ECG) solution for use in decentralized clinical trials. The clinical-grade solution is the most advanced patient-centric ECG offering within the company’s cardiac monitoring portfolio, pairing data readings comparable to clinical, site-based ECGs with Philips leading cloud-based data collection and analysis services. This latest addition to Philips’ digitally enabled suite of monitoring solutions helps to drive innovation across the care continuum and support the decentralized clinical trial space.
Patient attrition is one of the biggest issues faced by clinical trial sponsors seeking regulatory approval for new therapies. Attrition over the course of a study can reduce the quality of its findings and can lead to longer, more expensive trials that require higher than optimal recruiting rates to compensate. Voluntary patient withdrawal is often tied to disease progression or the prolonged inconvenience of adhering to protocol regimens and repetitive site visits [1]. By offering the consistent and reliable standards of a 12-lead ECG in the comfort and convenience of a patient’s home, Philips at-home ECG solution aims to improve trial recruitment, compliance and patient retention by reducing the need for and burden of site visits.
“Our customers are seeking solutions that will help them to address key challenges that can stand in the way of extracting meaningful insights from their clinical trials,” said Andy Broadway, General Manager of Ambulatory Monitoring and Diagnostics at Philips. “Our growing portfolio of remote monitoring solutions help to curb patient attrition by reducing the amount of site visits required during the trial period, helping to improve both the quality of the outcome and the patient experience overall.”
Leveraging PCA 500 ECG patch data recording technology, the at-home solution allows clinical trial participants to record data with quality comparable to site-based ECGs at home. The solution’s innovative body-worn patch ensures compliant 12-lead ECG placement and near real-time, highly secure data transmission without the need for recurring site visits, onsite technician, or home nurses.
Philips offers a complete range of clinically validated ambulatory cardiac diagnostics and monitoring services and associated expertise to its cardiac care portfolio, including its BioTel Research capabilities that have already supported more than 2,000 clinical trials in 72 countries. These comprehensive offerings provide industry-leading technology and data management that streamlines the clinical trials process and ensures optimal performance. The at-home, 12-lead ECG solution is now available in select markets across North America, Europe and Asia.
[1] Hui D, Glitza I, Chisholm G, Yennu S, Bruera E. Attrition rates, reasons, and predictive factors in supportive care and palliative oncology clinical trials. Cancer. 2013;119(5):1098-1105. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568443/
For further information, please contact:
Meredith Amoroso
Philips Global Press Office
Tel: +1 724-584-8991
E-mail: meredith.amoroso@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachments
- Philips introduces first at-home, 12 lead ECG integrated solution for decentralized clinical trials
- Philips new at-home, 12 lead ECG solution helps to reduce need for site visits during clinical trials
FAQ
What is the new ECG solution by Philips (PHG)?
How does the ECG solution improve clinical trials?
What technology does Philips use for the ECG solution?
In which markets is the Philips ECG solution available?
How many clinical trials has Philips supported?
